Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) and PTC Therapeutics (NASDAQ:PTCT)

Madrigal Pharmaceuticals (NASDAQ:MDGL) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Madrigal Pharmaceuticals and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
PTC Therapeutics	-3.80%	N/A	-1.32%

Analyst Ratings

This is a summary of current ratings for Madrigal Pharmaceuticals and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	2	15	0	2.78
PTC Therapeutics	2	3	10	1	2.62

Madrigal Pharmaceuticals currently has a consensus price target of $699.20, indicating a potential upside of 62.23%. PTC Therapeutics has a consensus price target of $94.93, indicating a potential upside of 50.63%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Madrigal Pharmaceuticals is more favorable than PTC Therapeutics.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and PTC Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40 million	10.39	-$288.28 million	($12.89)	-33.44
PTC Therapeutics	$1.01 billion	5.21	$682.64 million	($0.58)	-108.66

PTC Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Summary

PTC Therapeutics beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.